Page 41 - Read Online

Page 14 of 15 Pacheco et al. J Cancer Metastasis Treat 2020;6:49 I http://dx.doi.org/10.20517/2394-4722.2020.85

Copyright
©The Author(s) 2020.

REFERENCES
1. Picci P, Manfrini M, Donati DM, et al. Diagnosis of musculoskeletal tumors and tumor-like conditions 2nd edition. Switzerland:Springer
Nature; 2020.
2. Bovée JVMG, Bloem JL, Flanagan AM, et al. WHO Classification of Tumours of Soft Tissue and Bone. 5th edition. Lyon: International
Agency for research on cancer; 2020.
3. Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. AFIP atlas of tumor pathology. Tumors of the bones and joints. 4th series.
Washington, DC: The American Registry of Pathology;2005.
4. Ahmed AR, Tan TS, Unni KK, Collins MS, Wenger DE, Sim FH. Secondary chondrosarcoma in osteochondroma: report of 107 patients.
Clin Orthop Relat Res 2003;193-206.
5. Jones KB, Piombo V, Searby C, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc
Natl Acad Sci U S A 2010;107:2054-9.
6. de Andrea CE, Wiweger M, Prins F, Bovée JV, Romeo S, Hogendoorn PC. Primary cilia organization reflects polarity in the growth plate
and implies loss of polarity and mosaicism in osteochondroma. Lab Invest 2010;90:1091-101.
7. Matsumoto K, Irie F, Mackem S, Yamaguchi Y. A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of
heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci U S A 2010; 107:10932-7.
8. Jennes I, Pedrini E, Zuntini M, et al. Multiple osteochondromas: mutation update and description of the multiple osteochondromas
mutation database (MOdb). Hum Mutat 2009;30:1620-7.
9. de Andrea CE, Reijnders CM, Kroon HM, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of
outgrowth of cells with functional EXT. Oncogene 2012;31:1095-104.
10. Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol
2005;6:530-41.
11. Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix Biol 2018;71-72:28-39.
12. Hallor KH, Staaf J, Bovée JV, et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin
Cancer Res 2009;15:2685-94.
13. de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol
2012;226:219-28.
14. de Andrea CE, Zhu JF, Jin H, Bovée JV, Jones KB. Cell cycle deregulation and mosaic loss of Ext1 drive peripheral
chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. J Pathol 2015;236:210-8.
15. Nielsen GP, Rosenberg AE, Deshpande V, Hornicek FJ, Kattapuram SV, Rosenthal DI. Diagnostic Pathology: Bone. 2nd ed. Philadelphia,
PA: Elsevier; 2017.
16. Vanel D, De Paolis M, Monti C, Mercuri M, Picci P. Radiological features of 24 periosteal chondrosarcomas. Skeletal Radiol
2001;30:208-12.
17. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and
periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224:334-43.
18. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-29.
19. van Maldegem AM, Gelderblom H, Palmerini E, et al. Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer
2014;120:3159-64.
20. Papagelopoulos PJ, Galanis EC, Mavrogenis AF, et al. Survivorship analysis in patients with periosteal chondrosarcoma. Clin
OrthopRelat Res 2006;448:199-207.
21. Bertoni F, Boriani S, Laus M, Campanacci M. Periosteal chondrosarcoma and periosteal osteosarcoma. Two distinct entities. J Bone Joint
Surg Br 1982;64:370-6.
22. Cleven AH, Zwartkruis E, Hogendoorn PC, et al. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare
chondrosarcoma subtype. Histopathology 2015;67:483-90.
23. Pansuriya TC, van Eijk R, d’Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell
hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011;43:1256-61.
24. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
25. Suijker J, Baelde HJ, Roelofs H, Cleton-Jansen AM, Bovée JV. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2
blocks osteoblast differentiation in vitro and in vivo. Oncotarget 2015;6:14832-42.
26. Jin Y, Elalaf H, Watanabe M, et al. Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-
specific histone modifications to cartilage- and bone-related genes. PLoS One 2015;10:e0131998.
27. Czerniak B. Dorfman and Czerniak’s Bone Tumors. 2nd edition. Philadelphia: Saunders; 2016.
28. Goedhart LM, Ploegmakers JJ, Kroon HM, Zwartkruis EC, Jutte PC. The presentation, treatment and outcome of periosteal
chondrosarcoma in the Netherlands. Bone Joint J 2014;96:823-8.
29. Ruengwanichayakun P, Gambarotti M, Frisoni T, et al. Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. Hum
Pathol 2019;91:11-8.
30. Bertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer